Translational Development Acquisition Corp.(TDACW)Earnings, Financials & Key Ratios
TDACW•NASDAQ•Banking & Credit
Price updated Jun 19, 2026
AboutTranslational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.Show more
- Net Interest Income$125K
- Total Revenue$1M
- Net Income-$71K+85.4%
- Return on Equity-0.08%
- Net Interest Margin0.07%
- Efficiency Ratio18.42%
- ROA-0.08%+100.0%
- Equity / Assets96.43%+100.4%
- Book Value per Share41.67+33341.3%
TDACW Key Insights
Translational Development Acquisition Corp. (TDACW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Efficient operations: 18.4% efficiency ratio
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Well capitalized: 96.4% equity/assets
- ✓Healthy dividend yield of 2.5%
- ✓Diversified revenue: 100.0% from non-interest income
✗Weaknesses
- ✗Weak NIM of 0.1%
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TDACW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TDACW Price & Volume
Translational Development Acquisition Corp. (TDACW) stock price & volume — 10-year historical chart
Loading chart...
TDACW Growth Metrics
Translational Development Acquisition Corp. (TDACW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM970.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM485.68%
Return on Capital
10 Years-159.39%
5 Years-238.48%
3 Years-474.69%
Last Year-0.23%
TDACW Peer Comparison
Translational Development Acquisition Corp. (TDACW) competitors in SPACs and acquisition vehicles — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BRTX | 3.68M | 0.41 | -0.26 | -10.3% | -30.9% | -423.84% | ||
 HCAI | 8.75M | 7.77 | -0.21 | -83.94% | -262.32% | 0.01 | ||
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 ICLR | 11.18B | 146.00 | 50.34 | -0.37% | 5.98% | 5.2% | 0.39 | |
 MEDP | 13.14B | 460.20 | 30.12 | 19.97% | 17.19% | 120.89% | 0.55 | |
 PRA | 1.27B | 24.65 | 24.90 | -2.67% | 6.04% | 4.95% | 0.32 | |
 BFLY | 2.33B | 8.90 | -28.71 | 18.96% | -73.63% | -36.79% | 0.10 |
Compare TDACW vs Peers
Translational Development Acquisition Corp. (TDACW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TDACW Income Statement
Translational Development Acquisition Corp. (TDACW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Net Interest Income | 0 | 0 | 0 | 348.43K | 0 | 0 | 125.35K | 3.67M |
NII Growth % | - | - | - | - | - | - | - | 0% |
Net Interest Margin % | 0% | 0% | 0% | 540.68% | 0% | 0% | 0.07% | 2.04% |
Interest Income | 0 | 2.47M | 4.32M | 348.43K | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 2.47M | 4.32M | 0 | 0 | 0 | 508.56K | -60.12K |
Loan Loss Provision | 387 | -2.47M | -4.32M | 0 | 0 | 0 | -187.69K | 590.19K |
Non-Interest Income | 0 | -2.47M | -4.32M | -348.43K | 0 | 0 | 1.07M | 553.29K |
Non-Interest Income % | - | - | - | - | - | - | 100% | 100% |
Total Revenue | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.07M▲ 0% | 553.29K▲ 0% |
Revenue Growth % | - | - | - | - | - | - | - | 0% |
Non-Interest Expense | 0 | -699.33K | -1.1M | -1.39M | 70.66K | 485.55K | 196.36K | 4.99M |
Efficiency Ratio | - | - | - | - | - | - | 18.42% | 901.08% |
Operating Income | -387▲ 0% | -699.33K▼ 180606.5% | -1.1M▼ 57.3% | -1.39M▼ 26.0% | -70.66K▲ 94.9% | -485.55K▼ 587.1% | -196.36K▲ 59.6% | -915.58K▲ 0% |
Operating Margin % | - | - | - | - | - | - | -18.42% | -165.48% |
Operating Income Growth % | - | -180606.46% | -57.31% | -25.96% | - | -587.14% | 59.56% | - |
Pretax Income | -387▲ 0% | 1.78M▲ 459719.6% | 3.22M▲ 81.2% | -1.03M▼ 131.8% | -70.66K▲ 93.1% | -485.55K▼ 587.1% | -71.01K▲ 85.4% | 4.76M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | -6.66% | 860.04% |
Income Tax | 0 | 374.64K | 690.82K | 217.09K | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 21.06% | 21.43% | -21.16% | 0% | 0% | 0% | 0% |
Net Income | -387▲ 0% | 1.4M▲ 362912.1% | 2.53M▲ 80.4% | -1.24M▼ 149.1% | -70.66K▲ 94.3% | -485.55K▼ 587.1% | -71.01K▲ 85.4% | 4.76M▲ 0% |
Net Margin % | - | - | - | - | - | - | -6.66% | 860.04% |
Net Income Growth % | - | 362912.14% | 80.41% | -149.08% | - | -587.14% | 85.37% | 970.22% |
Net Income (Continuing) | -387 | 1.4M | 2.53M | -1.24M | -70.66K | -485.55K | -71.01K | 4.76M |
EPS (Diluted) | -0.00▲ 0% | 0.24▲ 240100.0% | 0.36▲ 50.0% | -0.17▼ 147.2% | -0.02▲ 89.8% | -0.12▼ 589.7% | -0.02▲ 86.5% | 0.28▲ 0% |
EPS Growth % | - | - | 50% | -147.22% | - | -589.66% | 86.5% | 485.68% |
EPS (Basic) | -0.00 | 0.24 | 0.36 | -0.17 | -0.02 | -0.12 | -0.02 | - |
Diluted Shares Outstanding | 5.76M | 5.76M | 7.1M | 7.18M | 4.05M | 4.05M | 4.05M | 17.25M |
TDACW Balance Sheet
Translational Development Acquisition Corp. (TDACW) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash & Short Term Investments | 143.4K | 1.26M | 74.43M | 64.38K | 2.23K | 2.02K | 438.17K | 727.18K |
Cash & Due from Banks | 143.4K | 1.26M | 55.46K | 973 | 2.23K | 2.02K | 438.17K | 47.15K |
Short Term Investments | 0 | 0 | 74.38M | 63.41K | 0 | 0 | 0 | 0 |
Total Investments | 0 | 207.75M | 148.75M | 63.41K | 0 | 0 | 174.35M | 179.9M |
Investments Growth % | - | - | -28.4% | -99.96% | - | - | - | 0% |
Long-Term Investments | 0 | 207.75M | 74.38M | 0 | 0 | 0 | 174.35M | 708.46M |
Accounts Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Goodwill & Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 21.63T | 39.57M |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 9.06T | 9.06M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 12.57T | 30.51M |
PP&E (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Assets | 404.24K | 1.2K | 1.2K | 63.41K | 383.01K | 0 | -21.63T | -39.57M |
Total Current Assets | 143.4K | 1.32M | 158.38K | 1.04K | 54.23K | 2.02K | 650.23K | 80.58K |
Total Non-Current Assets | 404.24K | 207.75M | 74.38M | 63.41K | 383.01K | 0 | 174.35M | 179.9M |
Total Assets | 547.64K▲ 0% | 209.07M▲ 38077.1% | 74.54M▼ 64.3% | 64.44K▼ 99.9% | 437.24K▲ 578.5% | 2.02K▼ 99.5% | 175M▲ 8659008.3% | 179.98M▲ 0% |
Asset Growth % | - | 38077.12% | -64.35% | -99.91% | - | -99.54% | 8659008.31% | 9189939.17% |
Return on Assets (ROA) | -0.07% | 1.34% | 1.79% | -3.33% | -16.16% | -221.08% | -0.08% | 2.68% |
Accounts Payable | 0 | 159.51K | 159.38K | 326 | 0 | 1.25K | 16.19K | 0 |
Total Debt | 525K | 850K | 360K | 5.08M | 259K | 347.5K | 347.5K | 100K |
Net Debt | 381.6K | -405.82K | 304.54K | -973 | 256.77K | 345.48K | -90.67K | 52.85K |
Long-Term Debt | 0 | 425K | 180K | 0 | 0 | 0 | 0 | 0 |
Short-Term Debt | 525K | 425K | 180K | 5.08M | 259K | 347.5K | 6.11T | 100K |
Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 6.04M | 6.04M |
Total Current Liabilities | 525K | 958.31K | 1.02M | 5.4K | 459.39K | 509.68K | 210.3K | 422.85K |
Total Non-Current Liabilities | 0 | 425.85K | 180K | 0 | 0 | 0 | 6.04M | 6.04M |
Total Liabilities | 525K | 204.07M | 69.54M | 10.43K | 459.34K | 509.68K | 6.25M | 6.46M |
Total Equity | 22.64K▲ 0% | 203.08M▲ 896832.8% | 68.49M▼ 66.3% | 54.23M▼ 20.8% | -22.11K▼ 100.0% | -507.66K▼ 2196.3% | 168.75M▲ 33341.4% | 173.52M▲ 0% |
Equity Growth % | - | 896832.76% | -66.28% | -20.82% | - | -2196.26% | 33341.43% | 131214% |
Equity / Assets (Capital Ratio) | 4.13% | 97.13% | 91.88% | 84150.81% | -5.06% | -25119.15% | 96.43% | 96.41% |
Return on Equity (ROE) | -1.71% | 1.38% | 1.87% | -2.03% | - | - | -0.08% | 2.78% |
Book Value per Share | 0.00 | 35.28 | 9.64 | 7.56 | -0.01 | -0.13 | 41.67 | 10.06 |
Tangible BV per Share | 0.00 | 35.28 | 9.64 | 7.56 | -0.01 | -0.13 | -5340906.48 | 7.77 |
Common Stock | 3.74K | 7.07K | 7.15K | 49.23K | 466 | 466 | 18.33B | 179.9M |
Additional Paid-in Capital | 0 | 0 | 0 | 0 | 24.53K | 24.53K | 0 | 0 |
Retained Earnings | -2.36K | 1.4M | 3.93M | 3.13K | -47.11K | -532.66K | -5.6M | -6.38M |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 16.88B | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TDACW Cash Flow Statement
Translational Development Acquisition Corp. (TDACW) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -387 | -603.66K | -1.53M | -1.85M | -97.16K | -204 | -851.45K | -1.3M |
Operating CF Growth % | - | -155885.79% | -152.69% | -21.2% | - | 99.79% | -417275.49% | -2974.32% |
Net Income | -387 | 1.4M | 2.53M | -1.24M | -71 | -485.55K | -71.01K | 4.76M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.03M |
Deferred Taxes | 0 | 851 | -851 | -217.09K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 381.6K | -2.75M | -2.84M | -1.24M | -97.02K | 482.34K | -120.63K | -6.67M |
Working Capital Changes | -381.6K | 742.95K | -1.22M | 856.07K | -75 | 3.01K | -659.81K | -419.1K |
Cash from Investing | 0 | -205.28M | 137.7M | 11.32M | 0 | 0 | -174.22M | -177.57M |
Purchase of Investments | 0 | -205.28M | -500K | 0 | 0 | 0 | -174.22M | -174.22M |
Sale/Maturity of Investments | 0 | 0 | 1000K | 0 | 0 | 0 | 0 | 0 |
Net Investment Activity | 0 | -205.28M | 500K | 0 | 0 | 0 | -174.22M | -174.22M |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Investing | 0 | 0 | 0 | 11.32M | 0 | 0 | 0 | -3.35M |
Cash from Financing | 87.83K | 206.99M | -137.38M | -8.55M | 99.39K | 0 | 175.51M | 184.53M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -125.35K | -5.67M |
Share Repurchases | 0 | 0 | -137.13M | -13.45M | 0 | 0 | 0 | 0 |
Stock Issued | 0 | 207.73M | 0 | 0 | -125.61K | 0 | 169.05M | 169.05M |
Net Stock Activity | 0 | 207.73M | -137.13M | -13.45M | -125.61K | 0 | 169.05M | 169.05M |
Debt Issuance (Net) | 0 | 0 | 0 | 0 | 225K | 0 | -393.46K | -563.46K |
Other Financing | 87.83K | 206.99M | -137.38M | -8.55M | 0 | 0 | 6.98M | 21.71M |
Net Change in Cash | 87.45K▲ 0% | 1.11M▲ 1172.1% | -1.2M▼ 207.9% | 917.33K▲ 176.4% | 2.23K▼ 99.8% | -204▼ 109.2% | 436.15K▲ 213900.5% | 455.33K▲ 0% |
Exchange Rate Effect | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash at Beginning | 55.95K | 143.4K | 1.26M | 55.46K | 0 | 2.23K | 2.02K | 35.26K |
Cash at End | 143.4K | 1.26M | 55.46K | 972.79K | 2.23K | 2.02K | 438.17K | 47.15K |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Free Cash Flow | -387▲ 0% | -603.66K▼ 155885.8% | -1.53M▼ 152.7% | -1.85M▼ 21.2% | -145▲ 100.0% | -204▼ 40.7% | -851.45K▼ 417275.5% | -2.46M▲ 0% |
FCF Growth % | - | -155885.79% | -152.69% | -21.2% | - | -40.69% | -417275.49% | -5972.82% |
TDACW Banking Ratios
Translational Development Acquisition Corp. (TDACW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 1.38% | 1.87% | -2.03% | - | - | -0.08% | 2.78% |
Return on Assets (ROA) | 1.34% | 1.79% | -3.33% | -16.16% | -221.08% | -0.08% | 2.68% |
Net Interest Margin | 0% | 0% | 540.68% | 0% | 0% | 0.07% | 2.04% |
Efficiency Ratio | - | - | - | - | - | 18.42% | 901.08% |
Equity / Assets | 97.13% | 91.88% | 84150.81% | -5.06% | -25119.15% | 96.43% | 96.41% |
Book Value / Share | 35.28 | 9.64 | 7.56 | -0.01 | -0.13 | 41.67 | 10.06 |
Dividend Payout | - | - | - | - | - | - | 79.86% |
Related:TDACW Dividend History·TDACW Revenue History·TDACW Price History·TDACW P/E History·TDACW Financial Ratios·TDACW Institutional Holders
TDACW Frequently Asked Questions
Translational Development Acquisition Corp. (TDACW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Translational Development Acquisition Corp. (TDACW) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Translational Development Acquisition Corp. (TDACW) is profitable, generating $4.8M in net income for fiscal year 2024 (-6.7% net margin).
Dividend & Returns
Yes, Translational Development Acquisition Corp. (TDACW) pays a dividend with a yield of 2.52%. This makes it attractive for income-focused investors.
Translational Development Acquisition Corp. (TDACW) has a return on equity (ROE) of -0.1%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Translational Development Acquisition Corp. (TDACW) has a net interest margin (NIM) of 0.1%. NIM has been under pressure due to interest rate environment.
Translational Development Acquisition Corp. (TDACW) has an efficiency ratio of 18.4%. This is excellent, indicating strong cost control.